Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00418574 · ClinicalTrials.gov registry record · Phase 2
Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients
A Phase 2 study, sponsored by Menarini Group.
- Terminated
- Registry status
- Phase 2
- Development phase
- 888
- Enrollment target
NCT00418574 is a Phase 2 study that was terminated before completion, run by Menarini Group. The registered enrollment target is 888 participants.
The verdict
NCT00418574, a Phase 2 study, was terminated before completion, sponsored by Menarini Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 888 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the benefit of vaccination with Abagovomab, an experimental immunotherapy in ovarian cancer patients. The benefit will be evaluated in terms of time the remission status is kept as well as prolongation of life expectancy.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Abagovomab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 888 participants |
| Start Date | 2006-12 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00418574
The ClinicalTrials.gov registry entry for NCT00418574 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 888 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Menarini Group, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00418574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00418574 about?
NCT00418574 is a clinical study titled "Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients". The purpose of this study is to evaluate the benefit of vaccination with Abagovomab, an experimental immunotherapy in ovarian cancer patients. The benefit will be evaluated in terms of time the remission status is kept as well as prolongation of life expectancy.
What is the current status of trial NCT00418574?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 888 participants. The study started on 2006-12. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00418574?
The interventions under investigation include: Placebo (BIOLOGICAL), Abagovomab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00418574?
This trial is sponsored by Menarini Group, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.